Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Clotilde Fournier (Marseille, France), Clotilde Fournier de Lesquen, Laurent Greillier, Pascale Tomasini, Helene Barazzutti, Frederic Fina, Fabrice Barlesi. Oncogenic drivers (OD) and matched targeted agents (TA): Impact on overall survival in patients with lung adenocarcinoma (LA)?. Eur Respir J 2015; 46: Suppl. 59, 4252

Member's Comments

No comment yet.

Related content which might interest you: Automated target-FISH lung cancer detection (LCD) test of induced sputum Source: International Congress 2015 – Developments in lung cancer diagnosis Year: 2015 Prognostic factors affecting survival in cases with lung cancer [A lung cancer mapping project in Turkey (LCMPT)] Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Prevalence of molecular changes in resected pulmonary adenocarcinomas Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level? Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Is residential radon associated with mutations in drivers genes in never smokers lung cancer cases? The case of EGFR and ALK Source: International Congress 2016 – Epidemiology and specific subgroups in lung cancer Year: 2016 LATE-BREAKING ABSTRACT: Prognostic value of microRNAs expression in stage I-IIIA lung adenocarcinoma (AC) Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome) Year: 2013 Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 EGFR frequency and response to chemotherapy in a Brazilian NSCLC population Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Lung cancer in Berlin – NET of the lung; analysis of subgroups and impact on survival (2000 – 2008) Source: Annual Congress 2013 –Epidemiology, screening and diagnosis of lung cancer Year: 2013 Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Early response detection in systemic lung cancer treatment using cell-free methylated SHOX2 (mSHOX2) plasma DNA Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Breast metastasis from primary EGFR-mutated lung carcinoma or primary tumor? Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016